26Apr

New Non-Invasive Urine Test for Bladder Cancer Diagnosis Showcasing at BAUS 2018

Alpha Laboratories Ltd. (Eastleigh, UK) is delighted to have been appointed as the exclusive distributor for Arquer Diagnostics Ltd (“Arquer”) in the UK and Republic of Ireland. Arquer (Sunderland, UK) is an in-vitro diagnostic company developing breakthrough diagnostic tests for the detection of bladder and prostate cancer.

Its non-invasive cancer diagnostic tests are based on the MCM5 (minichromosome maintenance protein) platform. The first Arquer product is ADXBLADDER, a bladder cancer diagnostic test, and a number of clinical trials are running to validate many other indications.

Come and see us on stand #128 for more information about this exciting new test. To celebrate the launch of ADXBLADDER we’re giving away a Bose® SoundLink Revolve Water-resistant Portable Bluetooth Speaker – visit the stand and complete an entry form.

For more information please visit www.alphalabs.co.uk/adxbladder or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk

Related

D-dimer point-of-care testing for DVT considered ‘game-changer’ in ambulatory care

Crawley, UK – 07 February 2019 – Radiometer Limited’s AQT90 FLEX analysers have been used in a su...

Read More >

SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of molecular diagnostic test

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement ...

Read More >

Novodiag® Bacterial GE+, a new diagnostic test for on-demand detection of bacterial pathogens

Espoo, Finland, April 17th, 2018 - Mobidiag, a Finnish molecular diagnostics company, today announce...

Read More >

Abingdon Health and DCN Diagnostics partner on commercialisation of AppDx m-Health technology

Abingdon Health and DCN Diagnostics have announced a commercial partnership to provide Abingdon Heal...

Read More >

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, ...

Read More >

Shift to Paradigm™ Low-Retention Tips

A New Standard of Excellence in Your Application

Read More >